Prof. Dr. Çağlayan Geredeli

• Tumeurs du sein 15 publications
  Source : OpenAlex / PubMed MeSHVoir les publications
• Carcinome pulmonaire non à petites cellules 9 publications
• Tumeurs du poumon 9 publications
• Tumeurs colorectales 8 publications
• Tumeurs du pancréas 3 publications
• Tumeurs du cerveau 3 publications
• Adénocarcinome 3 publications
• Tumeurs du côlon 2 publications
• Tumeurs du foie 2 publications
• Tumeurs de l’estomac 2 publications
• Obésité 2 publications

Domaines d’intérêt médical indiqués par le médecin lui-même sur sa page du site de l’établissement. Source : medicalpark.com.tr.

Expérience

• 19941995 Kütahya Gediz Devlet Hastanesimedicalpark.com.tr
• 19951999 Dicle Üniversitesi Tıp Fakültesi Hastanesi İÇ hastalıklarımedicalpark.com.tr
• 20002001 Şırnak Silopi Devlet hastanesi İç Hastalıkları Uzmanı ve Başhekimimedicalpark.com.tr
• 20022003 Ankara Polatlı SSK Hastanesi İç Hatalıkları Uzmanımedicalpark.com.tr
• 20042007 Ankara Polatlı Hayrettin Ekmen Devlet Hastanesi İç Hastalıkları uzmanı ve Başhekimimedicalpark.com.tr
• 20082009 Ankara Polatlı Duatepe Devlet Hastanesi İç Hastalıkları Uzmanı ve Başhekim Yard.medicalpark.com.tr
• 20102012 Necemttin Erbakan Üniversitesi Meram Tıp Fakültesi Tıbbi Onkoloji Bölümümedicalpark.com.tr
• 20132014 Konya Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanımedicalpark.com.tr
• 20152017 İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanımedicalpark.com.tr
• 20182021 İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Eğitim görevlisimedicalpark.com.tr
• 20222023 İstanbul Prof Dr. Cemil Taşcıoğlu Şehir Hastanesi Tıbbi Onkoloji Eğitim Sorumlusumedicalpark.com.tr

Formation

• Formation1994 Selçuk Üniversitesi Tıp Fakültesimedicalpark.com.tr
• Formation2012 NEÜ Meram Tıp Fakültesi Tıbbi Onkoloji Uzmanımedicalpark.com.tr
• Formation2018 Tıbbi Onkoloji Doçentimedicalpark.com.tr

• SpécialitéOncologie médicalemedicalpark.com.trD’après la source
• Nom du service dans la sourceMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trD’après la source
• Établissementİstinye Üniversitesi Medical Park Gaziosmanpaşamedicalpark.com.trD’après la source
• Sujet de travailTumeurs du seinDéduit de 15 publications · Version du modèle —D’après la source
• Publications121 publicationsOpenAlex, ORCIDD’après la source
• ORCID0000-0002-3982-7465ORCIDD’après la source
• Dernière synchronisation4 novembre 2026 20:26https://www.medicalpark.com.tr/hekimler/caglayan-geredelimedicalpark.com.tr

1. Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry

   Anadolu Kliniği Tıp Bilimleri Dergisi, 2026

   DOI 10.21673/anadoluklin.1675424 Texte intégral en libre accèsSource : OpenAlex

2. The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study

   Medicina, 2026

   DOI 10.3390/medicina62010214 PMID 41597500 Texte intégral en libre accèsSource : OpenAlex

3. Predictors of Recurrence Following Curative-Intent Local Therapy for Oligometastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study from the Turkish Oncology Group (TOG)

   Eurasian Journal of Medical Investigation, 2026

   DOI 10.14744/ejmi.2612571 Source : ORCID

4. KRAS Mutasyonu Saptanmayan Metastatik Kolorektal Kanserli Hastalarda Anti-EGFR Kullanımı-Ulusal Onco-Colon Çalışması Gerçek Yaşam Verleri

   DergiPark (Istanbul University), 2025

   Source : OpenAlex

5. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

   BMC Cancer, 2025

   DOI 10.1186/s12885-025-15287-2 PMID 41275151 Texte intégral en libre accèsSource : OpenAlex

6. The Efficiency of Concomitant Antibiotic Usage On Survival Outcomes of Nivolumab-Treated Metastatic Renal Cell Carcinoma Patients: A Multicenter Experience

   Research Square, 2025

   DOI 10.21203/rs.3.rs-6066659/v1 Texte intégral en libre accèsSource : OpenAlex

7. Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome

   Indian Journal of Cancer, 2024

   DOI 10.4103/ijc.ijc_1283_20 PMID 39960699 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

8. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

   Journal of Oncology Pharmacy Practice, 2024

   DOI 10.1177/10781552241241004 PMID 38613329 Texte intégral en libre accèsSource : OpenAlex

9. Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes

   Cancers, 2024

   DOI 10.3390/cancers16223880 PMID 39594835 8 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

10. The impact of body mass index on the progression free survival of CDK 4/6 inhibitors in metastatic breast cancer patients

    Research Square, 2024

    DOI 10.21203/rs.3.rs-4144594/v1 Texte intégral en libre accèsSource : ORCID